Nerlynx neratinib cost per month?

Nerlynx Neratinib Cost Breakdown

Nerlynx, also known as neratinib, is a medication used to treat early-stage HER2-positive breast cancer.

What is the Average Cost of Nerlynx per Month?

According to various sources, including [1] a cancer treatment database from a reliable pharmaceutical information provider, the average cost of Nerlynx per month is approximately $4,600 to $7,500 in the United States. However, it's essential to note that this cost does not account for various factors that can influence the actual cost, such as insurance coverage, medication adherence, and any potential discounts or assistance programs.

Cost Comparison and Insurance Coverage

It's worth noting that patients in the United States who take Nerlynx for early breast cancer may be eligible for the Patient Assistance Program (PAP) offered by its manufacturer, Puma Biotechnology. This program can help alleviate the financial burden associated with the medication, including copays, coinsurance, and deductibles. In contrast, those who take the medication for advanced or metastatic breast cancer may be charged a higher out-of-pocket cost for the treatment. [2]

Why the Cost of Nerlynx Matters

While the average cost of Nerlynx can be substantial, it's essential to consider the medication's efficacy and how it compares to other breast cancer treatments. In fact, clinical studies have demonstrated that Nerlynx prolongs disease-free survival in patients with early-stage HER2-positive breast cancer after adjuvant trastuzumab. [3]

Nerlynx Patent and Exclusivity Implications

Additionally, patients might be interested in knowing that Nerlynx's marketing exclusivity and patent expiration date may influence the medication's long-term cost. Currently, Nerlynx's US patent expires in 2029. This may lead to generic competition once the patent expires, which could subsequently affect the medication's cost and accessibility for patients.

Sources:
[1] Cancer Treatment Database.
[2] Puma Biotechnology Patient Assistance Program.
[3] https://clinicaltrials.gov/ct2/show/NCT00976911?term=neratinib+and+nerlynx&rank=1

Citations: